JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, cilt.128, sa.4, ss.808-822, 2011 (SCI-Expanded)
Background: Subcutaneous allergen-specific immunotherapy (SIT) has an early onset of action, whereas repeated injections and safety concerns have limited its use in the pediatric age group. Meanwhile, the improved safety profile of the sublingual route has been accepted as an alternative despite its relatively late onset of action.